A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease

British Journal of Radiology

Volumn 89, Issue 1060, 2016, Pages

  Scott, Joseph ^a   Underwood, Jonathan ^a   Garvey, Lucy J ^a   Mora Peris, Borja ^a   Winston, Alan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; EMTRICITABINE; INOSITOL; LOPINAVIR; MARAVIROC; N ACETYLASPARTIC ACID; RITONAVIR; TENOFOVIR; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BASAL GANGLION; BRAIN FUNCTION; BRAIN METABOLISM; CEREBRAL METABOLITE RATIO; CLINICAL ARTICLE; GRAY MATTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; METABOLIC PARAMETERS; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER; BLOOD; BRAIN; BRAIN DISEASES; COMPARATIVE STUDY; HIV INFECTIONS; METABOLISM; PROCEDURES;

BIOMARKERS; BRAIN; BRAIN DISEASES; CCR5 RECEPTOR ANTAGONISTS; CYCLOHEXANES; HIV INFECTIONS; HUMANS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; TRIAZOLES;

EID: 84989933258     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20150979     Document Type: Article

References (25)

1. Joint United Nations Programme on HIV/ AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic 2013. Switzerland: UNAIDS; 2013.
2. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43: 2245-52. doi: http://dx.doi.org/10.1212/WNL.43.11.2245
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60. doi: http://dx.doi.org/10.1056/ NEJM199803263381301
4. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 (Suppl. 2): 115-21.
5. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243-50.
6. Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med 2009; 10: 246-52. doi: http://dx. doi.org/10.1111/j.1468-1293.2008.00679.x
7. Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIVassociated dementia. Neurology 2004; 63: 2084-90. doi: http://dx.doi.org/10.1212/01. WNL.0000145763.68284.15
8. Price RW, Peterson J, Fuchs D, Angel TE, Zetterberg H, Hagberg L, et al. Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol 2013; 8: 1147-58. doi: http://dx.doi.org/10.1007/s11481-013-9491-3
9. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naïve HIV patients. NeuroImage 2002; 17: 1638-48. doi: http://dx.doi.org/10.1006/nimg.2002.1254
10. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999; 52: 100-8. doi: http://dx.doi.org/10.1212/WNL.52.1.100
11. Lentz MR, Kim WK, Kim H, Soulas C, Lee V, Venna N, et al. Alterations in brain metabolism during the first year of HIV infection. J Neurovirol 2011; 17: 220-9. doi: http://dx. doi.org/10.1007/s13365-011-0030-9
12. Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiology 2009; 64: 12-21. doi: http://dx.doi.org/ 10.1016/j.crad.2008.07.002
13. Magnetic Resonance Spectroscopy, InTech. Available from: http://www.intechopen.com/ books/magnetic-resonance-spectroscopy/ quantification-improvements-of-1hmrssignals
14. Pels P, Ozturk-Isik E, Swanson MG, Vanhamme L, Kurhanewicz J, Nelson SJ, et al. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed 2006; 19: 188-97. doi: http://dx.doi.org/10.1002/ nbm.1008
15. Mullins PG, Rowland L, Bustillo J, Bedrick EJ, Lauriello J, Brooks WM. Reproducibility of 1H-MRS measurements in schizophrenic patients. Magn Reson Med 2003; 50: 704-7. doi: http://dx.doi.org/10.1002/mrm.10598
16. Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, et al. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J Antimicrob Chemother 2012; 67: 206-12. doi: http://dx.doi.org/10.1093/ jac/dkr427
17. Else L, Watson V, Tjia J, Hughes A, Siccardi M, Khoo S, et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65. doi: http://dx.doi.org/10.1016/j. jchromb.2010.03.036
18. Naressi A, Couturier C, Devos J, Janssen M, Mangeat C, De Beer R, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 12: 141-52.
19. Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained leastsquares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data. Magn Reson Med 2011; 65: 1-12. doi: http://dx.doi.org/10.1002/ mrm.22579
20. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997; 129: 35-43. doi: http://dx.doi.org/10.1006/ jmre.1997.1244
21. van den Boogaart A. A users guide to the magnetic resonance user interface software package MRUI manual V96.3. Delft, Netherlands. 1997.
22. Poullet JB, Sima DM, Simonetti AW, De Neuter B, Vanhamme L, Lemmerling P, et al. An automated quantitation of short echo time MRS spectra in an open source software environment: AQSES. NMR Biomed 2007; 20: 493-504. doi: http://dx.doi.org/10.1002/ nbm.1112
23. Vanhamme L, Fierro RD, Van Huffel S, de Beer R. Fast removal of residual water in proton spectra. J Magn Reson 1998; 132: 197-203. doi: http://dx.doi.org/10.1006/ jmre.1998.1425
24. Mohamed MA, Barker PB, Skolasky RL, Selnes OA, Moxley RT, Pomper MG, et al. Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging 2010; 28: 1251-7. doi: http://dx.doi.org/ 10.1016/j.mri.2010.06.007
25. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32. doi: http://dx.doi.org/10.1128/AAC.49.11.4721-4732.2005